Olmesartan medoxomil for the treatment of hypertension in children and adolescents

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 177-181

  Tocci, Giuliano ^a   Volpe, Massimo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Adolescents; Antihypertensive treatment; Children; High blood pressure; Hypertension; Olmesartan medoxomil

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE; OLMESARTAN; TETRAZOLE DERIVATIVE;

ADOLESCENT; ANIMAL; BLOOD PRESSURE; CHILD; DRUG EFFECT; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

ADOLESCENT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHILD; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; IMIDAZOLES; RISK ASSESSMENT; TETRAZOLES; TREATMENT OUTCOME;

EID: 79961204130     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S11672     Document Type: Review

References (50)

1. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-1187.
2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289(19):2560-2572.
3. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens. 2004;18(3):139-185.
4. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000; 356(9246):1955-1964.
5. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527-1535.
6. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressurelowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165(12):1410-1419.
7. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008; 336(7653):1121-1123.
8. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289(18):2363-2369.
9. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43(1):10-17.
10. Nakamura K, Barzi F, Lam TH, et al. Cigarette smoking, systolic blood pressure, and cardiovascular diseases in the Asia-Pacific region. Stroke. 2008;39(6):1694-1702.
11. Martiniuk AL, Lee CM, Lawes CM, et al. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens. 2007;25(1):73-79.
12. Barzi F, Patel A, Woodward M, et al. A comparison of lipid variables as predictors of cardiovascular disease in the Asia Pacific region. Ann Epidemiol. 2005;15(5):405-413.
13. Kelishadi R, Ardalan G, Gheiratmand R, et al. Blood pressure and its influencing factors in a national representative sample of Iranian children and adolescents: the CASPIAN Study. Eur J Cardiovasc Prev Rehabil. Dec 2006;13(6):956-963.
14. Genovesi S, Antolini L, Gallieni M, et al. High prevalence of hypertension in normal and underweight Indian children. J Hypertens. 2011; 29(2):217-221.
15. Rumboldt M, Pavlicevic I, Kuzmanic M, Rumboldt Z. Prevalence of hypertension in school children. J Hypertens. 2008;26(3):610-611; author reply 611-612.
16. Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics. 2004;113(3 Pt 1):475-482.
17. Sorof JM. Prevalence and consequence of systolic hypertension in children. Am J Hypertens. 2002;15(2 Pt 2):57S-60S.
18. Kelishadi R. Childhood overweight, obesity, and the metabolic syndrome in developing countries. Epidemiol Rev. 2007;29:62-76.
19. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372(9634): 224-233.
20. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438): 937-952.
21. Bao W, Threefoot SA, Srinivasan SR, Berenson GS. Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study. Am J Hypertens. 1995;8(7): 657-665.
22. Chen W, Srinivasan SR, Ruan L, Mei H, Berenson GS. Adult hypertension is associated with blood pressure variability in childhood in blacks and whites: the bogalusa heart study. Am J Hypertens. 2011;24(1): 77-82.
23. Berenson GS, Wattigney WA, Bao W, Nicklas TA, Jiang X, Rush JA. Epidemiology of early primary hypertension and implications for prevention: the Bogalusa Heart Study. J Hum Hypertens. 1994;8(5): 303-311.
24. Volpe M, Erhardt LR, Williams B. Managing cardiovascular risk: the need for change. J Hum Hypertens. 2008;22(2):154-157.
25. Williams B. Recent hypertension trials: implications and controversies. J Am Coll Cardiol. 2005;45(6):813-827.
26. Lurbe E, Cifkova R, Cruickshank JK, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009;27(9):1719-1742.
27. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114(2 Suppl 4th Report):555-576.
28. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Pediatrics. 1996;98(4 Pt 1):649-658.
29. Yamada S. Pleiotropic effects of ARB in metabolic syndrome. Curr Vasc Pharmacol. 2011;9(2):158-161.
30. Saitoh S, Takeishi Y. Pleiotropic effects of ARB in diabetes mellitus. Curr Vasc Pharmacol. 2011;9(2):136-144.
31. Papadopoulos DP, Papademetriou V, Makris TK. On target to dual block RAS? Angiology. 2009;60(6):739-749.
32. Simonetti GD, Rizzi M, Donadini R, Bianchetti MG. Effects of antihypertensive drugs on blood pressure and proteinuria in childhood. J Hypertens. 2007;25(12):2370-2376.
33. Hazan L, Hernandez Rodriguez OA, Bhorat AE, Miyazaki K, Tao B, Heyrman R. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension. 2010;55(6):1323-1330.
34. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs. 2002;62(9): 1345-1353; discussion 1354-1346.
35. Volpe M, Musumeci B, De Paolis P, Savoia C, Morganti A. Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? J Hypertens. 2003;21(8):1429-1443.
36. Brunner HR. Olmesartan medoxomil: current status of its use in monotherapy. Vasc Health Risk Manag. 2006;2(4):327-340.
37. Puchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens Suppl. 2001;19(1):S41-S48.
38. Usui M, Egashira K, Tomita H, et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation. 2000;101(3):305-310.
39. Takemoto M, Egashira K, Tomita H, et al. Chronic angiotensinconverting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension. 1997;30(6): 1621-1627.
40. Tomita H, Egashira K, Ohara Y, et al. Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension. 1998;32(2):273-279.
41. Koike H, Sada T, Mizuno M. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J Hypertens Suppl. 2001;19(1):S3-S14.
42. Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs. 2008;68(9):1239-1272.
43. Unger T, McInnes GT, Neutel JM, Bohm M. The role of olmesartan medoxomil in the management of hypertension. Drugs. 2004;64(24): 2731-2739.
44. Brousil JA, Burke JM. Olmesartan medoxomil: an angiotensin IIreceptor blocker. Clin Ther. 2003;25(4):1041-1055.
45. Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol. 2001;41(5):515-527.
46. Von Bergmann K, Laeis P, Puchler K, Sudhop T, Schwocho LR, Gonzalez L. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens Suppl. 2001;19(1):S33-S40.
47. Stumpe KO. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Clin Ther. 2004;26 Suppl A: A33-A37.
48. Wehling M. Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control? Clin Ther. 2004;26 Suppl A:A21-A27.
49. Laeis P, Puchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl. 2001;19(1):S21-S32.
50. Muir VJ, Keating GM. Olmesartan medoxomil: in children and adolescents with hypertension. Drugs. 2010;70(18):2439-2447.